» Articles » PMID: 18823034

Cancer-specific Survival Outcomes Among Patients Treated During the Cytokine Era of Kidney Cancer (1989-2005): a Benchmark for Emerging Targeted Cancer Therapies

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2008 Oct 1
PMID 18823034
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The management of renal cell carcinoma (RCC) is evolving toward less extirpative surgery and the use of targeted therapy. The authors set out to provide a benchmark against which emerging therapies should be measured.

Methods: A prospective database including clinical and pathological variables for 1632 patients with RCC treated between 1989 and 2005 was queried. Patients were stratified using the University of California-Los Angeles Integrated Staging System (UISS) into low-, intermediate-, and high-risk groups. Disease-specific survival (DSS) was measured. Response to systemic therapy for patients with advanced disease was assessed.

Results: Nephrectomy was performed in 1492 patients. Overall 5-, 10-, and 15-year DSS was 55%, 40%, and 29%. For localized disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 97% and 92%, 81% and 61%, and 62% and 41%, respectively. For metastatic disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 41% and 31%, 18% and 7%, and 8% and 0%, respectively. Patients with metastatic disease receiving immunotherapy (n=453) had complete response in 7% (median survival [MS], 120+ months), partial response in 15% (MS, 42.8 months), stable disease in 33% (MS, 38.6 months), and progressive disease in 45% (MS, 11.6 months).

Conclusions: Most patients with localized RCC do well with surgery alone, but effective adjuvant therapy is needed for patients identified as at high risk for recurrence. For advanced disease, newer targeted and potentially less toxic treatments should be at least as effective as those achieved with aggressive surgical resection and immunotherapy.

Citing Articles

Exploring the role of natural bioactive molecules in genitourinary cancers: how far has research progressed?.

Islam F, Nath N, Zehravi M, Khan J, Jashim S, Charde M Nat Prod Bioprospect. 2023; 13(1):39.

PMID: 37843642 PMC: 10579213. DOI: 10.1007/s13659-023-00400-4.


Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future.

Srour S, Akin S J Immunother Precis Oncol. 2023; 6(1):19-30.

PMID: 36751657 PMC: 9888521. DOI: 10.36401/JIPO-22-7.


Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review.

Kim T, Lee Y, Koo K Investig Clin Urol. 2022; 63(5):486-498.

PMID: 36067994 PMC: 9448669. DOI: 10.4111/icu.20220103.


Size-based isolation and detection of renal carcinoma cells from whole blood.

de Alwis R, Hansson J, Lindgren D, Schoch S, Tejera A, Scholtz B Mol Clin Oncol. 2022; 16(5):101.

PMID: 35463211 PMC: 9022084. DOI: 10.3892/mco.2022.2534.


Avelumab plus axitinib . sunitinib for advanced renal-cell carcinoma.

Zhang Y, Wu S Transl Cancer Res. 2022; 8(Suppl 6):S585-S588.

PMID: 35117136 PMC: 8798318. DOI: 10.21037/tcr.2019.06.39.